Summary of HR 1843: Transparency in Generic Drug Applications

Bill Information:
- Bill Number: HR 1843
- Title: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
- Status: Introduced in House
- Introduced Date: March 05, 2025
- Classification: Bill

Purpose and Intent

HR 1843 aims to enhance transparency in the process of evaluating generic drug applications under the Federal Food, Drug, and Cosmetic Act. The bill seeks to provide clearer communication from the Secretary of Health and Human Services regarding the bioequivalence of generic drugs to their brand-name counterparts, thereby facilitating a more informed application process for manufacturers.

Key Provisions

The bill introduces several important amendments to Section 505(j)(3) of the Federal Food, Drug, and Cosmetic Act:

1. Information Disclosure:

   • Upon request, the Secretary must inform applicants whether their generic drug is qualitatively and quantitatively the same as the listed drug.
   • If the drug is not the same, the Secretary must disclose which ingredients differ and specify any quantitative deviations.

2. Determination Consistency:

   • Once a determination is made that a drug is equivalent, it cannot be rescinded unless:
     • The formulation of the listed drug has changed due to safety or effectiveness concerns.
     • An error in the initial determination has been identified.

3. Guidance Issuance:

   • The Secretary of Health and Human Services is required to issue or update guidance within one year of the bill's enactment, detailing how to assess qualitative and quantitative equivalence, including considerations for pH adjusters.
   • The guidance process includes a 60-day comment period for stakeholders.

4. Immediate Applicability:

   • The provisions of the new section will take effect upon the bill's enactment, regardless of when the guidance is finalized.

Affected Parties

• Generic Drug Manufacturers: The bill primarily impacts companies that submit abbreviated new drug applications (ANDAs) for generic drugs, providing them with clearer criteria and feedback from the FDA.
• Consumers and Patients: Increased transparency may lead to more reliable generic drug options, potentially improving access to affordable medications.
• Health Care Providers: Providers will benefit from clearer information regarding the equivalence of generic drugs, aiding in prescribing decisions.

Procedural Aspects

• Introduced Date: March 05, 2025
• Legislative Actions:
  • Referred to the House Committee on Energy and Commerce on the same day of introduction.
• Sponsors:
  • Primary Sponsor: Neal P. Dunn
  • Cosponsor: Kevin Mullin

Related Legislation

• Companion Bills:
  • HR 1768
  • S 1302
  • S 891

This summary provides an overview of HR 1843, highlighting its objectives, key provisions, and the potential impact on stakeholders involved in the generic drug market. The bill represents a significant step towards improving the transparency and reliability of generic drug applications in the United States.